Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye

The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data...

Cijeli opis

Bibliografski detalji

Glavni autori:	Umut Devrim Binay, Faruk Karakeçili, Bilgehan Aygen, Ayşin Kılınç Toker, İlhami Çelik, Neşe Demirtürk, Tuğçe Şimşek Bozok, Leyla Dursun, Fethiye Akgül, Güle Çınar, Özgür Günal, Ali Asan, Eyüp Arslan, Fatma Yılmaz Karadağ, Orçun Barkay, İrem Akdemir, Funda Şimşek, Emine Türkoğlu Yılmaz, Zeynep Ravza Eğilmez, Süda Tekin, The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK)
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-06-01
Serija:	Viruses
Teme:	sofosbuvir/velpatasvir/voxilaprevir hepatitis C treatment real-world data
Online pristup:	https://www.mdpi.com/1999-4915/17/7/931
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!